Pentobarbital will decrease the extent or result of fentanyl transmucosal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to your decrease in fentanyl plasma concentrations, deficiency of efficacy or, perhaps, advancement of the withdrawal syndrome in the patient https://thomasg185oqq3.59bloggers.com/profile